Current and Upcoming Treatment Modalities in Myasthenia Gravis
| Autor: | Sara Hooshmand, Raghav Govindarajan, Megan Sweeney, Cho Junsang, Swathi Beladakere Ramaswamy, Shivangi Singh |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
business.industry Molecular pathogenesis MEDLINE Target audience General Medicine medicine.disease Myasthenia gravis Review article Clinical Practice Clinical trial Neurology Treatment modality Myasthenia Gravis medicine Humans Neurology (clinical) Intensive care medicine business |
| Zdroj: | Journal of Clinical Neuromuscular Disease. 23:75-99 |
| ISSN: | 1522-0443 |
| DOI: | 10.1097/cnd.0000000000000377 |
| Popis: | Myasthenia gravis (MG) is one of the extensively studied autoimmune disorder. There has been a dramatic increase in research to further understand molecular pathogenesis of MG and clinical trials for new drugs in MG treatment in the past decade. This review article is to consolidate the available information in simple terms with students, residents, and fellows as target audience for easy learning and help application of this knowledge to clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|